TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22672713
Drug: External-hexagon implants
Normalized name: CATHETER,EXTERNAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: External-hexagon implants with flat-to-flat implant-abutment interface
Study: 18543158
Drug: Dynamic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dynamic treatment protocol (passive extension with a rubber band system)
Study: 18543158
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment protocol (early active extension of the thumb)
Study: 15967908
Drug: Laparoscopic surgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laparoscopic surgery with 4 mg . kg(‐1) . min(‐1) dextrose infusion
Study: 15967908
Drug: Open surgery
Normalized name: BOTTLE OPENER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open surgery with 4 mg . kg(‐1) . min(‐1) dextrose infusion
Study: 12623838
Drug: Pamidronate (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamidronate (90 mg IV on day 1) + IL-2 (0.25 to 3 x 10^6 IU/m2 continuous IV infusion from day 3 to day 8)
Study: 12623838
Drug: Pamidronate +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamidronate + modified IL-2 (6-hour bolus IV infusions from day 1-6)
Study: 12623838
Drug: Pamidronate +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamidronate + low-dose IL-2
Study: 10580431
Drug: CSII plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CSII plus troglitazone (600 mg/day)
Study: 10580431
Drug: CSII plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CSII plus metformin (1,700 mg/day)
Study: 31142947
Drug: Oral Itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Itraconazole for 4 weeks
Study: 31142947
Drug: Oral Terbinafine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Terbinafine for 4 weeks
Study: 11387364
Drug: 40 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 Gy total fractionated dose for the clinically noninvolved extended field (arm A)
Study: 11387364
Drug: 30 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 Gy total fractionated dose for the clinically noninvolved extended field (arm B)
Study: 9407458
Drug: cilazapril (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: cilazapril (2 mg/day)
Study: 7714164
Drug: 200 or
Normalized name: Mag-200 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 or 400 mg RU486 administered on day LH+2
Study: 7714164
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no RU486 treatment)
Study: 2967936
Drug: Duovent (fenoterol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duovent (fenoterol 0.1 mg/ipratropium 0.04 mg per puff)
Study: 2967936
Drug: Salbutamol (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol (0.1 mg per puff)
Study: 21975318
Drug: Adjuvant HAI‐FUDR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant HAI‐FUDR plus dexamethasone (Dex) and concurrent systemic chemotherapy including oxaliplatin or irinotecan
Study: 21975318
Drug: Modern systemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modern systemic chemotherapy alone
Study: 15909609
Drug: Fructose 1.6-diphosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fructose 1.6-diphosphate (FDP) administered i.v. for 7 consecutive days
Study: 2513207
Drug: Standard metrifonate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard metrifonate treatment (3 doses of 7.5 mg.kg‐1 at two‐weekly intervals)
Study: 2513207
Drug: Abbreviated metrifonate
Normalized name: Metrifonate
DrugBank: Metrifonate (DB11473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abbreviated metrifonate treatment (3 doses of 5 mg.kg‐1 in one day)
Study: 22898035
Drug: BIIB021 600
Normalized name: BIIB021
DrugBank: BIIB021 (DB12359)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIIB021 600 mg twice a week (BIW)
Study: 22898035
Drug: BIIB021 400
Normalized name: BIIB021
DrugBank: BIIB021 (DB12359)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIIB021 400 mg three times a week (TIW)
Study: 11527645
Drug: GTN (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: GTN (0.6 mg/h/24 h)
Study: 11527645
Drug: PETN (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: PETN (60 mg orally three times a day)
Study: 9419950
Drug: UDCA 600
Normalized name: UDCA
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: UDCA 600 mg per day
Study: 2820289
Drug: Alternating chemotherapy
Normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternating chemotherapy (cyclophosphamide, doxorubicin, vincristine alternating with etoposide (100 mg/m2 on days 1 to 3) and cisplatin (25 mg/m2 on days 1 to 3) every 3 weeks for six treatment cycles)
Study: 2820289
Drug: Standard chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard chemotherapy (cyclophosphamide (1000 mg/m2), doxorubicin (50 mg/m2), and vincristine (2 mg) every 3 weeks for six courses)
Study: 30374055
Drug: Testing for
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testing for immunoglobulin M (IgM) and G (IgG) responses against 20 microbes associated with TBD
Study: 26799451
Drug: Topical 25%
Normalized name: urea topical 25% topical lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 25% sodium metabisulfite
Study: 16034446
Drug: Atomoxetine (ATX)
DrugBank: Atomoxetine (DB00289)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atomoxetine (ATX) 60 mg
Study: 14512180
Drug: Dexamethasone (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (0.2 mg/kg/day start, tapering doses)
Study: 11022398
Drug: Tryptophan (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tryptophan (2 to 4 g per day) with fluoxetine (20 mg per day)
Study: 11022398
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with fluoxetine (20 mg per day)
Study: 1321490
Drug: 1:200,000 epinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1:200,000 epinephrine in a four percent articaine‐HCl solution
Study: 1321490
Drug: 1:100,000 epinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1:100,000 epinephrine in a four percent articaine‐HCl solution
Study: 6514177
Drug: Pirlindole with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirlindole with ethanol (0.4 g 17 vol%/kg)
Study: 24551029
Drug: Prophylactic low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic low dose penicillin V (6 months for first episode, 12 months for recurrent cellulitis)
Study: 24551029
Drug: Prophylactic low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic low dose penicillin V
Study: 20118492
Drug: Fluvastatin 80
Normalized name: fluvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin 80 mg once daily
Study: 20118492
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (PEG-IFN-alpha 2b and ribavirin)
Study: 15642859
Drug: Prednisone (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (0.75 mg/kg daily for the first 10 days of each month for 6 months)
Study: 15642859
Drug: Placebo (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.75 mg/kg daily for the first 10 days of each month for 6 months)
Study: 8384278
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg Lomefloxacin (200 mg b.i.d.)
Study: 8384278
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg Lomefloxacin (200 mg t.i.d.)
Study: 25193943
Drug: No-pain control
Normalized name: Biochemistry Heel No Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-pain control treatment
Study: 20613472
Drug: Propofol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (2 microg/ml)
Study: 19024258
Drug: Implant brushing
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Implant brushing on machined surfaces
Study: 12647006
Drug: Intratunical instillation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intratunical instillation of 2.5 mL of 0.5 % bupivacaine combined with 10 mg/ml methylprednisolone
Study: 12647006
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving only analgesics postoperatively by intramuscular route
Study: 11004352
Drug: Ethyl icosapentate
Normalized name: Ethyl icosapentate
DrugBank: Icosapent ethyl (DB08887)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ethyl icosapentate 1800 mg daily and estriol (E3) 2 mg daily (eicosapentaenoic acid group, n = 69)
Study: 11004352
Drug: Estriol (E3)
Normalized name: Estriol
DrugBank: Estriol (DB04573)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estriol (E3) 2 mg daily (control group, n = 72)
Study: 8976475
Drug: Spinal manipulative
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal manipulative therapy (SMT) combined with trunk strengthening exercises (TSE)
Study: 8976475
Drug: Spinal manipulative
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal manipulative therapy (SMT) combined with trunk stretching exercises
Study: 8976475
Drug: Nonsteroidal anti-inflammatory
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsteroidal anti-inflammatory drug (NSAID) therapy combined with trunk strengthening exercises (TSE)
Study: 1361797
Drug: Neomycin sulphate
Normalized name: Neomycin sulphate
DrugBank: Neomycin (DB00994)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neomycin sulphate nasal ointment
Study: 24253788
Drug: Actifuse combined
Normalized name: Actidose
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Actifuse combined with 5 mL of bone marrow aspirate (n = 26)
Study: 24253788
Drug: rhBMP-2 (4.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhBMP-2 (4.2 mg, n = 26)
Study: 20823643
Drug: Telmisartan (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan (40 mg per day)
Study: 20823643
Drug: Candesartan (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan (8 mg per day)
Study: 20823643
Drug: Telmisartan (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan (40 mg per day) in obese subjects
Study: 15691639
Drug: HDFU (5FU
Approvals — FDA: no, EMA: no, PMDA: no
Description: HDFU (5FU 3 g/m2 intravenously, 24 h infusion, weekly for 6 weeks)
Study: 15691639
Drug: 5FU+FA+CDDP (5FU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5FU+FA+CDDP (5FU 2.0 g/m2 i.v. with folinic acid 500 mg/m2, 2 h-infusion, weekly for 6 weeks + cisplatin 50 mg/m2, once every two weeks for 6 weeks)
Study: 10376776
Drug: Zinc (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc (70 mg, once per week)
Study: 10376776
Drug: Zinc and
Normalized name: Zinc and/or zinc compound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc and Vitamin A (70 mg Zn and 3030 RE vitamin A, once per week)
Study: 30515970
Drug: adalimumab (TNF
Approvals — FDA: no, EMA: no, PMDA: no
Description: adalimumab (TNF inhibitor)
Study: 30515970
Drug: ustekinumab (IL-12/23
Approvals — FDA: no, EMA: no, PMDA: no
Description: ustekinumab (IL-12/23 inhibitor)
Study: 30342645
Drug: Ropivacaine injection
Normalized name: ROPivacaine Injection
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ropivacaine injection (7.5% ropivacaine, 10 mL total, 5 mL each into both uterosacral ligaments)
Study: 30342645
Drug: Saline injection
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline injection (10 mL total, 5 mL each into both uterosacral ligaments)
Study: 10710805
Drug: 10% dextrose
Normalized name: Aminosyn II 4.25% in 10% Dextrose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% dextrose and 0.075% lidocaine in bacteriostatic water (active solution)
Study: 10710805
Drug: Control solution
Normalized name: Nausea Control Solution
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control solution absent 10% dextrose
Study: 26630718
Drug: Red Cross
Normalized name: Cotton Red Cross 2oz
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red Cross Canker Sore Medication
Study: 1490488
Drug: Droxicam (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droxicam (20 mg single dose)
Study: 1490488
Drug: Droxicam (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droxicam (20 mg/day for 30 consecutive days)
Study: 1490488
Drug: Piroxicam (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piroxicam (20 mg single dose)
Study: 1490488
Drug: Piroxicam (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piroxicam (20 mg/day for 30 consecutive days)
Study: 3858894
Drug: 1-mg DST
Normalized name: DST
DrugBank: Dihydrostreptomycin (DB11512)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-mg DST
Study: 3858894
Drug: 2-mg DST
Normalized name: DST
DrugBank: Dihydrostreptomycin (DB11512)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-mg DST
Study: 3858894
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 1-mg and 2-mg DST with 119 semi-consecutive admissions
Study: 30921979
Drug: Intravenous lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lidocaine infusion (IVLI) 2 mg/minute for 4 hours
Study: 30921979
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline solution 0.9% (Control)
Study: 25758436
Drug: Contrast-enhanced ultrasound
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contrast-enhanced ultrasound (CEUS) used before, during and after HIFU treatment (Group A)
Study: 25758436
Drug: No CEUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: No CEUS administered (Group B)
Study: 21051458
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment (rate control)
Study: 15190528
Drug: MCC-135 5
Normalized name: Trastuzumab-MCC-DM1
DrugBank: Trastuzumab emtansine (DB05773)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: MCC-135 5 mg, twice daily
Study: 15190528
Drug: MCC-135 25
Normalized name: Trastuzumab-MCC-DM1
DrugBank: Trastuzumab emtansine (DB05773)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: MCC-135 25 mg, twice daily
Study: 15190528
Drug: MCC-135 50
Normalized name: Trastuzumab-MCC-DM1
DrugBank: Trastuzumab emtansine (DB05773)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: MCC-135 50 mg, twice daily
Study: 12587476
Drug: Definitive radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Definitive radiotherapy only, delivered with megavoltage linear accelerator, combined with intracavitary brachytherapy in some patients, total tumor dose range 55-75 Gy
Study: 9572815
Drug: Creatine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine supplementation (30 g creatine + 30 g dextrose per day)
Study: 9572815
Drug: Placebo (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (30 g dextrose per day)
Study: 8589479
Drug: Human leukocyte
Normalized name: Human leukocyte antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human leukocyte interferon-alpha cream (2x10(6) IU/g) applied thrice daily for 5 consecutive days
Study: 775616
Drug: Colo-rectal operations
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colo-rectal operations
Study: 31291984
Drug: Pharmacopuncture with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacopuncture with hominis placenta extract (PLC), administered twice a week for a total of 18 sessions over 9 weeks.
Study: 31291984
Drug: Injections of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injections of normal saline, administered at the same acupoints during the same period as PLC.
Study: 17014060
Drug: Non-protease inhibitors
Normalized name: Protease inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-protease inhibitors (non-PIs)
Study: 15341255
Drug: Metformin (850
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (850 mg twice a day) + Diane35 (for the first two months)
Study: 7967853
Drug: Self-administered symptom
Normalized name: Pamprin Multi-Symptom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administered symptom severity scale
Study: 7967853
Drug: Self-administered functional
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administered functional status scale
Study: 7967853
Drug: Self-administered activities
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administered activities of daily living scale
Study: 3410484
Drug: Pyridostigmine bromide
Normalized name: Pyridostigmine Bromide
DrugBank: Pyridostigmine (DB00545)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pyridostigmine bromide (60 mg)
Study: 3410484
Drug: Lactose (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactose (60 mg)
Study: 29871197
Drug: Sodium pyruvate
Normalized name: Sodium Pyruvate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium pyruvate nasal spray
Study: 17646506
Drug: 5 mL
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mL saline (distention)
Study: 17646506
Drug: 2 mL
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mL (nondistention)
Study: 16238116
Drug: Fluvastatin (Lescol)
Normalized name: fluvastatin Oral Capsule [Lescol]
DrugBank: Fluvastatin (DB01095)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluvastatin (Lescol) 40 mg once daily at bedtime for 6 weeks
Study: 16238116
Drug: Atorvastatin (Sortis)
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atorvastatin (Sortis) 10 mg once daily at bedtime for 6 weeks
Study: 12396958
Drug: H. pylori
Normalized name: H. PYLORI AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: H. pylori eradication treatment with amoxicillin, clarithromycin, and omeprazole for 7 days
Study: 7531394
Drug: G‐CSF 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF 200 micrograms per square meter per day subcutaneously until ANC > 1,500/mm³ (group B)
Study: 7531394
Drug: G‐CSF prophylactically
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF prophylactically used in high-dose cytosine arabinoside regimens (group C)
Study: 7531394
Drug: No G‐CSF
Approvals — FDA: no, EMA: no, PMDA: no
Description: No G‐CSF used (group A)
Study: 31577772
Drug: Rational Emotive
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rational Emotive Behavioral Therapy (REBT)
Study: 27836862
Drug: 5-azacitidine (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-azacitidine (75 mg/m2) for 5 days prior to EOX chemotherapy (E: 50 mg/m2, O: 130 mg/m2, X: 625 mg/m2 twice daily for 21 days)
Study: 27836862
Drug: 5-azacitidine (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-azacitidine (75 mg/m2) for 3 days prior to EOX chemotherapy
Study: 25801556
Drug: Colistin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colistin plus ascorbic acid (2 g every 12 h)
Study: 21865979
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (FO) supplementation (5 mL daily)
Study: 21865979
Drug: Sunflower oil
Normalized name: Sunflower Oil
DrugBank: Sunflower oil (DB14329)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunflower oil (SO) supplementation (5 mL daily)
Study: 19625243
Drug: Glipizide XL,
Normalized name: GlipiZIDE XL, 5 mg oral tablet, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glipizide XL, 10 mg orally daily (G group)
Study: 19625243
Drug: Glipizide XL,
Normalized name: GlipiZIDE XL, 5 mg oral tablet, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glipizide XL, 10 mg orally daily, plus insulin glargine, 10 U daily (G+G group)
Study: 19625243
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment groups (G and G+G)
Study: 17346444
Drug: 1% PLA2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% PLA2 inhibitor-containing cream
Study: 14610134
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for spontaneous intracranial hypotension (exact treatment not specified)
Study: 10474118
Drug: GH therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH therapy (daily s.c. injections at a weekly dose of 8.2 mg/m(2) for 1.9-7.5 years)
Study: 9102589
Drug: 0.5% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% bupivacaine 1 ml (group A)
Study: 9102589
Drug: 1% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% bupivacaine 0.5 ml (group B)
Study: 6352655
Drug: 0.25 g
Normalized name: AMICAR 0.25 GM/mL Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 g ceftazidime twice daily for five days
Study: 6352655
Drug: 0.50 g
Normalized name: SALICYLIC ACID 0.50 g in 100 g TOPICAL SOAP [ORIPAN GOLD 100g]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.50 g ceftazidime twice daily for five days
Study: 6352655
Drug: 1.00 g
Normalized name: Niacinamide 1.00 g in 50 mL TOPICAL LIQUID [by selected hyaluron day serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.00 g ceftazidime twice daily for five days
Study: 31926918
Drug: Berberine 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Berberine 0.3 g twice daily
Study: 30670262
Drug: Almond oil
Normalized name: Almond Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almond oil (10 ml, two times daily for 30 days)
Study: 28629665
Drug: Tofacitinib monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib monotherapy (5 mg twice daily)
Study: 28629665
Drug: Tofacitinib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib plus methotrexate (5 mg twice daily)
Study: 28629665
Drug: Adalimumab plus
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adalimumab plus methotrexate (40 mg every other week)
Study: 21735192
Drug: 5 mg/day
Normalized name: Lyllana 0.05 MG/Day Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/day Letrozole (group 1)
Study: 21735192
Drug: 7.5 mg/day
Normalized name: nicotine 7.5 MG/Day 24 HR Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg/day Letrozole (group 2)
Study: 19370533
Drug: Intermittent docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent docetaxel chemotherapy (1, 2, or 3 cycles)